Nasus Pharma (NSRX) Other Non-Current Assets (2024 - 2025)
Nasus Pharma (NSRX) reported Other Non-Current Assets of $54000.0 for Q4 2025, up 100.0% on a YoY basis from $27000.0 in Q4 2024, and up 86.21% quarter-over-quarter from $29000.0 in Q2 2025.
Nasus Pharma (NSRX) Other Non-Current Assets (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Other Non-Current Assets for 2 years, with the latest figure at $54000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets rose 100.0% year-over-year to $54000.0; the trailing twelve-month figure through Dec 2025 stood at $54000.0 (up 100.0% YoY), and the FY2025 full-year result was $54000.0, up 100.0% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $54000.0, up from $29000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $54000.0 in Q4 2025, with the low at $27000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 3.18 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.23 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 14.11 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 10.54 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 6.08 Bn |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - | 54,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 54,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Dec 31, 2024 | 27,000.00 |